Halozyme Therapeutics (HALO) Tops Q2 EPS by 15c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $130.91 --0%
Revenue Growth %: +37.6%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
AES, SYRS, ZVOI, More
Revenue Growth %: +37.6%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
AES, SYRS, ZVOI, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.91, $0.15 better than the analyst estimate of $0.76. Revenue for the quarter came in at $231 million versus the consensus estimate of $208.94 million.
GUIDANCE:
Halozyme Therapeutics sees FY2024 EPS of $3.65-$4.05, versus the consensus of $4.72. Halozyme Therapeutics sees FY2024 revenue of $0.93-1.01 billion, versus the consensus of $0.98 billion.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercore ISI Upgrades Clorox (CLX) to In Line
- LyondellBasell Industries (LYB) PT Raised to $76 at Wells Fargo
- BioNano Genomics, Inc. (BNGO) files $400M mixed shelf
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
